Uric acid is the final product of purine metabolism, and its increased serum levels have been directly involved in the pathogenesis and natural history of a number of metabolic and cardiovascular diseases.
In particular, serum uric acid (SUA) has been associated with the risk of developing hypertension and subclinical vascular damage, as well as an increased risk of myocardial infarction, stroke, heart failure, and different arrhythmias (in particular atrial fibrillation) by affecting thickness, function, and other features of the vascular tissue. As regards metabolic diseases, SUA is not only associated with a risk of gout, but also metabolic syndrome, non-alcoholic fatty liver disease, obesity, and type 2 diabetes. The risk of type 2 diabetes macrovascular and microvascular complications are also associated with increased SUA levels.
Meanwhile, suboptimal SUA levels have been associated with an increased risk for cardiovascular disease mortality, in particular in type 2 diabetes patients. This suggests a use for SUA levels as markers of vascular injury and vascular related diseases, which in turn can be associated with endocrine comorbidities.
Beyond the rapidly increasing evidence relating SUA levels with all these risk factors, diseases, and mortality, more data are yet needed to clearly define the SUA cut-off associated with different outcomes in different populations and patients’ groups, where SUA is pathogenetic or an epiphenomenon, and the role of SUA-lowering therapies to prevent SUA related damages.
In this context, this Research Topic seeks to expand our understanding of SUA as it relates to vascular aging and endocrine morbidities such as diabetes, obesity, metabolic syndrome, and others. We welcome original research, review, mini review, perspective, and clinical trial articles.
Uric acid is the final product of purine metabolism, and its increased serum levels have been directly involved in the pathogenesis and natural history of a number of metabolic and cardiovascular diseases.
In particular, serum uric acid (SUA) has been associated with the risk of developing hypertension and subclinical vascular damage, as well as an increased risk of myocardial infarction, stroke, heart failure, and different arrhythmias (in particular atrial fibrillation) by affecting thickness, function, and other features of the vascular tissue. As regards metabolic diseases, SUA is not only associated with a risk of gout, but also metabolic syndrome, non-alcoholic fatty liver disease, obesity, and type 2 diabetes. The risk of type 2 diabetes macrovascular and microvascular complications are also associated with increased SUA levels.
Meanwhile, suboptimal SUA levels have been associated with an increased risk for cardiovascular disease mortality, in particular in type 2 diabetes patients. This suggests a use for SUA levels as markers of vascular injury and vascular related diseases, which in turn can be associated with endocrine comorbidities.
Beyond the rapidly increasing evidence relating SUA levels with all these risk factors, diseases, and mortality, more data are yet needed to clearly define the SUA cut-off associated with different outcomes in different populations and patients’ groups, where SUA is pathogenetic or an epiphenomenon, and the role of SUA-lowering therapies to prevent SUA related damages.
In this context, this Research Topic seeks to expand our understanding of SUA as it relates to vascular aging and endocrine morbidities such as diabetes, obesity, metabolic syndrome, and others. We welcome original research, review, mini review, perspective, and clinical trial articles.